Stay Informed on Corporate Sustainability

Author: Archie Villaflores

Pharmaceutical innovation reflects AI integration and strategic partnership models that compress development timelines whilst expanding market access. Progress emerges where diagnostic technology, distribution infrastructure, and computational drug discovery converge to strengthen commercial outcomes and patient impact. Revisiting a standout moment from last year, 'Deciphex wins Innovation of the Year at Pharma Industry Awards 2025' celebrates how AI-powered pathology platforms deliver measurable clinical impact through diagnostic workflow optimisation. This recognition establishes expectations for the 2026 awards, where real-world patient outcomes and operational scale will distinguish winning healthcare technologies. In addition, 'Bioreve Sciences secures nationwide retail partnership with Uniphar Group' demonstrates how Irish manufacturers leverage distribution agreements to expand market reach. Strategic retail partnerships enable supplement producers to scale domestic presence whilst maintaining supply chain control. Meanwhile, 'Takeda partners with Iambic on $1.7 billion AI drug discovery programme' illustrates how pharmaceutical companies deploy AI-driven molecular design platforms to compress preclinical timelines and reduce development costs. Multi-billion dollar partnerships validate computational approaches that predict protein binding and accelerate compound optimisation. These stories underscore a sector where technological capability, commercial infrastructure, and partnership strategy determine competitive advantage. Explore each article to understand how technology and collaboration are reshaping pharmaceutical sector performance.

Author: Archie Villaflores

Awarded for pioneering AI-powered diagnostics in 2025, Deciphex won Innovation of the Year at the Pharma Industry Awards, setting new standards for intelligent healthcare as the 2026 awards cycle approaches.

Author: Archie Villaflores

South Korea-based Sky Labs has signed an exclusive distribution deal with Japan-based Otsuka Pharmaceutical to launch its ring-type blood pressure monitor CART BP pro in Japan. The device is prescribed in over 1,700 medical institutions in Korea.

Author: Archie Villaflores

Japan-based Takeda Pharmaceutical has signed a partnership worth over $1.7 billion (€1.44 billion) with US-based privately held Iambic to develop AI-designed small-molecule drugs. The agreement targets cancer and gastrointestinal diseases with milestone payments and royalties.

Author: Archie Villaflores

ArrayPatch has announced the first close of a €3 million seed funding round led by Lakeside Capital. The Cork company is advancing ITZ-DerMap, a novel treatment for onychomycosis using its proprietary polymer-free DerMap platform technology.

Author: Archie Villaflores

Induchem Group Ireland has acquired Cork-based MAAS to strengthen its MedTech and pharmaceutical offering. The precision engineering firm generates approximately 50 per cent of turnover from these sectors.

Author: Archie Villaflores

Bioreve Sciences, an Ireland-based food supplement manufacturer, has secured a nationwide retail distribution partnership with Uniphar Group. The IDA-supported company recently completed a two-year facility investment programme in Longford.

Author: Archie Villaflores

The pharmaceutical sector is driven by breakthroughs in research, leadership development, and integrated project delivery. In this edition, we examine how organisations are combining innovation, operational agility, and inclusive strategies to set new benchmarks across the industry. In review of a notable milestone from last year, ‘Pharmaceutical and Molecular Biotechnology Research Centre wins Research & Development Achievement Award at Pharma Industry Awards 2025’ marks a high point in ocular drug delivery and sustainability-led laboratory practices. The centre’s achievement sets the stage for 2026, emphasising the ongoing impact of R&D on industry standards and patient outcomes. Moreover, ‘BioPharmaChem Skillnet Launches Inclusive Leadership Programme for 2026’ demonstrates how targeted leadership development can shape a culture of inclusion and strategic thinking. The programme equips participants with actionable tools to influence team dynamics and foster innovation across pharmaceutical organisations. Meanwhile, ‘Partnering for Success: Tandem Delivers End-to-End Project Excellence in the Life Science Sector’ highlights how collaborative, client-focused approaches enhance project delivery across complex life science initiatives. Effective coordination and technical expertise ensure operational certainty while driving measurable outcomes. These stories underline a common thread: scientific excellence, inclusive leadership, and operational mastery are shaping the next wave of growth and impact in pharma.

Author: Jed Nykolle Harme

BioPharmaChem Skillnet launches its 2026 Inclusive Leadership Programme, blending practical workshops and personalised coaching to develop self-aware, inclusive leaders.

Author: Jed Nykolle Harme

Tandem Project Management delivers end-to-end project excellence for life science companies, combining technical expertise, regulatory compliance, and operational agility to drive innovation and measurable results.